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INTRODUCTION
Utilizing interphase fluorescence in situ hybridiza-
tion  (FISH),  investigators  have  detected  chromo-
somal aberrations in over 80% of cases of chronic 
lymphocytic  leukemia  (CLL).  These  aberrations 
commonly involve chromosomes 11, 12, 13, and 17. 
Several retrospective studies suggest that the given 
chromosomal abnormalities are correlated with var-
ious disease parameters (Dohner et al., 2000; Wiktor 
et al., 2006). The general picture is dominated by 
unbalanced changes, mainly with deletions of well-
definable chromosomal regions. The abnormalities 
which seem to be associated with poor prognosis, 
e.g.,  +12,  del(17)(p13.1),  and  del(11)(q22.3),  are 
ones which have been shown to be secondary events, 
i.e.  present  in  some  of  the  malignant  B  cells  and 
developing at a later stage after the initiating event. 
On the other hand, deletion of one or more genes 
on the long arm of chromosome 13 is thought to 
be critical as an early event in CLL (Mehes, 2005). 
Moreover, 13q deletion has been linked with favor-
able prognosis, whereas trisomy 12 has been aso-
ciated  with  higher  proliferative  activity  and  short 
survival. In most previous studies, a low percent of 
coexistence of trisomy 12 and deletions of 13q14 was 
observed (Peterson et al., 1992; Avet-Loiseau et al., 
1996; Mould et al., 1996; Garcia-Marco et al., 1997; 
Hogan et al., 1999). 
We here describe two patients in whom interphase 
FISH analysis showed trisomy 12 and del(13)(q14.3) 
occurring in the same clone. Molecular cytogenetic 
results are compared with other clinical and labora-
tory parameters.
MATERIALS AND METHODS
Case reports
Patient 1
A 78-year-old man presented with fatigue and noc-
turnal sweating three years ago. The blood count 
showed: hemoglobin 13.6 g/dl, platelets 187 x 109/l, 
and  white  blood  cells  60  x  109/l.  The  differential 
count  showed  neutrophils  6%,  lymphocytes  92%, 
and  monocytes  2%.  Diagnosis  of  CLL  was  con-
firmed  by  immunophenotypic  analysis  performed 
on peripheral blood mononuclear cells, which dem-
onstrated the expression of mature B-cell markers 
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(CD19, CD22), the coexpression of CD5 and CD23, 
and the absence of sIg, CD 79b, FMC7, and CD38 
expression. 
The  bone  marrow  aspirate  was  hypercellular 
with 90% infiltration by small lymphocytes. Trephine 
biopsy  showed  a  diffuse  pattern  of  infiltration. 
According to the Rai staging system, the patient was 
considered to be in stage I. At his last check-up, he 
was without signs of progression in physical exami-
nation, but with increase of WBC up to 92 x 109/l. 
Patient 2
A 39-year-old man presented with cervical, axillary, 
and  inguinal  lymphoadenopathies  up  to  1.5  cm, 
without palpabile organomegaly. The blood count 
showed: hemoglobin 15.6 g/dl, platelets 181 x 109/l, 
and white blood cells 15.9 x 109/l. The differential 
count showed neutrophils 22%, lymphocytes 71%, 
and monocytes 7%. Initial ultrasonography of the 
abdomen showed no enlargement of the liver and 
spleen without retroperitoneal lymphadenopathy.
Diagnosis  of  CLL  was  confirmed  by  immu-
nophenotypic  analysis  performed  on  peripheral 
blood mononuclear cells, which demonstrated the 
expression of mature B-cell markers (CD19, CD22), 
the coexpression of CD5, CD23, sIg, CD 79b, and 
FMC7, and the absence of CD38 expression. 
The  bone  marrow  aspirate  was  hypercellular 
with 84% infiltration by small lymphocytes. Trephine 
biopsy showed an interstitial pattern of infiltration. 
At the time of diagnosis, the patient was considered 
to  be  in  stage  I  according  to  the  Rai  system.  At 
his  last  check-up,  he  was  with  general  peripheral 
lymphadenopathy up to 3 cm in diameter, palpabile 
splenomegaly and with increase of WBC up to 60 x 
109/l. 
Fluorescence in situ hybridization (FISH)
The  CLL  FISH  Probe  Panel,  consisting  of  Sets 
1  and  2,  was  used  (Vysis,  Downers  Grove,  IL). 
Probe Set 1 contains the SpectrumOrange LSI p53 
probe (17p13.1) and the SpectrumGreen LSI ATM 
(11q22.3)  probe.  Probe  Set  2  is  composed  of  the 
SpectrumOrange  D13S319  (13q14.3)  probe,  the 
SpectrumAqua  LSI13q34  (13q34)  probe,  and  the 
SpectrumGreen CEP 12 probe, which contains the 
D12Z3 alpha satellite sequence located at the cen-
tromere  of  chromosome  12.  The  FISH  procedure 
was  performed  on  peripheral  blood  cell  chromo-
some preparations according to the manufacturer’s 
instructions.
Two  hundred  nuclei  were  analyzed  for  each 
probe. The cutoff value for positivity was >10% for 
monosomies of  D13S319, 13q34, ATM, and p53; 
and >10% for trisomy 12.
Slides were examined using a Zeiss fluorescent 
microscope.
RESULTS
In patient No.1, interphase FISH analysis revealed 
trisomy 12 accompanied by 13q14.3 deletion in 68% 
of the nuclei scored (Fig. 1a). A clone with deletion 
of 13q14.3 but without trisomy 12 was observed in 
another 20% of the nuclei (Fig. 1b), and two signals 
for each probe (normal FISH pattern) were detected 
in the remaining 12% of the cells (Fig. 1c). In patient 
No.  2,  the  distribution  of  aberrant  and  normal 
clones  were  similar:  both  aberrations  (trisomy  12 
and 13q14.3 deletion) were noticed in 60% of the 
nuclei, deletion of 13q14.3 as a single aberration was 
noticed in 25% of the nuclei, and the normal FISH 
pattern for chromosome 12 and the 13.14.3 region 
was noticed in the remaining 15% of the cells. Since 
the same FISH probe set was used for both patients, 
the results for patient No. 2 are not presented in the 
figure.
Analysis  by  FISH  with  LSI  ATM/p53  probes 
showed a normal FISH pattern in all analyzed cells 
of  both  patients,  suggesting  that  deletions  of  the 
11q22.3  and  17p13.1  regions  were  not  present  in 
their karyotypes (data not shown).
DISCUSSION
The first chromosomal analyses performed on CLL 
patients identified trisomy 12 as the most frequent 
chromosomal abnormality, but in recent FISH stud-
ies  deletions  involving  13q  turned  out  to  be  the +12 AND DEL13q14 IN CLL PATIENTS 609
most  common  aberrations  (Peterson  et  al.,  1992; 
Avet-Loiseau et al., 1996; Mould et al., 1996; Garcia-
Marco et al., 1997; Hogan et al., 1999). 
It is speculated that +12 and del(13q)(14.3) have 
two  independent  molecular  genetic  pathways  and 
that consequently these abnormalities rarely coexist 
in the same pathologic clone. However, in relatively 
high  frequencies  of  cases  (up  to  17%)  with  both 
aberrations were found in two studies (Navarro et 
al., 1998; Chena et al., 2003).
Using  FISH,  we  found  the  coexistence  of  tri-
somy 12 and 13q14.3 deletion in the karyotypes of 
two patients with CLL diagnosis. The finding that 
trisomy  12  is  less  present  than  del(13q)(14.3)  in 
malignant clones indicates that +12 could not be the 
initial event in leukemogenesis and is rather a result 
of karyotypic evolution in our patients. 
The biological role of trisomy 12 in pathogenesis 
of CLL has not yet been clarified. It is speculated that 
a duplicated 12q13-q21.2 region may contain candi-
date oncogene(s) with a pathogenic role in CLL. 
The  clinical  significance  of  trisomy  12  and 
13q14  aberrations  was  first  reported  at  the  First 
and Second IWCCLL, where patients with trisomy 
12 were shown to have the shortest survival times 
among  patients  with  single  chromosomal  abnor-
malities. On the other hand, patients with structural 
abnormalities of chromosome 13 seemed to have a 
more favorable prognosis, exhibiting survival prob-
abilities similar to those with a normal karyotype 
(Juliusson et al., 1990; Juliusson et al., 1991). 
It was discovered that the deleted 13q14.3 region 
harbors  a  set  of  non-protein-coding  micro  RNA 
genes (Calin et al., 2004). These genes express short 
(approx. 20-30 bp) functional RNA molecules that 
would be capable of regulating distant sites of the 
genome by RNA interference. Mitochondrial RNA 
originating  from  the  13q14  locus  could  play  an 
important role in the regulation of cellular activa-
tion, and altered balance of this control mechanism 
therefore might slow down progression of the dis-
ease (Mehes, 2005).
Long-term clinical studies point to an unfavor-
able  nature  of  trisomy  12,  although  not  all  data 
could confirm a difference of survival rates com-
pared  to  patients  with  normal  karyotype  (Mehes, 
2005).  Furthermore,  patients  exhibiting  this  aber-
ration are frequently associated with advanced Rai 
stages, CD38 expression, and atypical morphology 
(Athanasiadou et al., 2006).
The prognostic relevance of the coexistence of 
trisomy 12 and deletion 13q14.3 is still unclear and 
one study (Chena et al., 2003) suggests a probable 
adverse prognosis for this group of patients.  
Fig. 1. FISH analysis using LSI D13S319 (red signals) and CEP 12 (green signals). Interphase nuclei representing all clones: 1a 
- trisomy 12 and 13q14.3 monosomy; 1b - monosomy 13q14.3 without trisomy 12; 1c - normal FISH pattern with two signals for 
chromosome 12 and 13q14.3 region. M. DENČIĆ-FEKETE ET AL. 610
To the contrary, our results show that both of 
our patients are in a stable phase of the disease (Rai 
I), without CD38 expression and atypical morphol-
ogy.  Undoubtedly,  clinical  and  molecular  data  of 
more cases are needed to determine the prognostic 
significance of coexistence of these abnormalities in 
CLL patients.
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Презенﾭтуﾭјемо два пацијенﾭта са дијагнﾭозом хро-
нﾭичﾭнﾭе лимфоцитнﾭе леуﾭкемије (CLL), код којих је 
анﾭализом инﾭтерфазнﾭе флуﾭоресценﾭтнﾭе in situ хибри-
дизације  (FISH)  откривенﾭо  присуﾭство  тризомије 
12 and del(13)(q14.3) уﾭ истом патолошком клонﾭуﾭ. 
Ове абнﾭормалнﾭости се ретко виђајуﾭ заједнﾭо, а прог-
нﾭостичﾭка знﾭачﾭајнﾭост њихове коегзистенﾭције је још 
уﾭвек нﾭејаснﾭа. Према нﾭеким литератуﾭрнﾭим подаци-
ма, за овуﾭ груﾭпуﾭ пацијенﾭата се предвиђа лоша прог-
нﾭоза  и  брза  прогресија  болести.  Суﾭпротнﾭо  томе, 
нﾭаши пацијенﾭти се нﾭалазе уﾭ стабилнﾭој фази боле-
сти, већ дуﾭже од годинﾭуﾭ данﾭа од како суﾭ ове абнﾭор-
малнﾭости детектованﾭе уﾭ њиховом кариотипуﾭ. Даље 
праћење ових пацијенﾭата је нﾭеопходнﾭо уﾭ циљуﾭ уﾭтвр-
ђивања  прогнﾭостичﾭке  знﾭачﾭајнﾭости  истовременﾭог 
присуﾭства ових аберација код CLL пацијенﾭата.